Clovis Oncology Inc. (NASDAQ:CLVS) was upgraded by stock analysts at Vetr from a “sell” rating to a “buy” rating in a research note issued to investors on Monday. The firm currently has a $39.27 target price on the biopharmaceutical company’s stock. Vetr‘s price target points to a potential upside of 5.06% from the company’s current price.

A number of other research firms have also recently issued reports on CLVS. SunTrust Banks Inc. initiated coverage on shares of Clovis Oncology in a research note on Friday, August 5th. They set a “buy” rating and a $25.00 target price for the company. Credit Suisse Group AG restated an “outperform” rating and set a $41.00 target price on shares of Clovis Oncology in a research note on Monday, October 10th. Zacks Investment Research cut shares of Clovis Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday, October 4th. Stifel Nicolaus raised their target price on shares of Clovis Oncology from $30.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, September 21st. Finally, Chardan Capital assumed coverage on shares of Clovis Oncology in a research note on Tuesday, October 25th. They set a “sell” rating and a $15.00 target price for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the stock. Clovis Oncology currently has a consensus rating of “Hold” and an average price target of $36.41.

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Shares of Clovis Oncology (NASDAQ:CLVS) opened at 37.38 on Monday. Clovis Oncology has a 1-year low of $11.57 and a 1-year high of $40.29. The company has a 50-day moving average of $32.24 and a 200-day moving average of $22.69. The company’s market cap is $1.44 billion.

Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.95) by $0.25. During the same quarter last year, the firm posted ($2.62) EPS. Equities analysts forecast that Clovis Oncology will post ($8.97) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This report was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2016/11/28/clovis-oncology-inc-clvs-upgraded-to-buy-by-vetr-inc.html.

Several large investors have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System raised its stake in shares of Clovis Oncology by 8.0% in the second quarter. State Board of Administration of Florida Retirement System now owns 22,819 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 1,693 shares during the period. DekaBank Deutsche Girozentrale raised its stake in shares of Clovis Oncology by 38.2% in the second quarter. DekaBank Deutsche Girozentrale now owns 22,800 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 6,300 shares during the period. Swiss National Bank raised its stake in shares of Clovis Oncology by 12.7% in the second quarter. Swiss National Bank now owns 55,050 shares of the biopharmaceutical company’s stock valued at $755,000 after buying an additional 6,200 shares during the period. California State Teachers Retirement System raised its stake in shares of Clovis Oncology by 13.1% in the second quarter. California State Teachers Retirement System now owns 66,645 shares of the biopharmaceutical company’s stock valued at $914,000 after buying an additional 7,702 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Clovis Oncology by 8.1% in the second quarter. Bank of New York Mellon Corp now owns 164,735 shares of the biopharmaceutical company’s stock valued at $2,260,000 after buying an additional 12,305 shares during the period.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

5 Day Chart for NASDAQ:CLVS

Receive News & Stock Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related stocks with our FREE daily email newsletter.